Stemline Therapeutics (STML) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- Mideast deal hopes lift Dow, S&P to records; SpaceX, AMD drag Nasdaq
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
Roth Affirms Stemline Therapeutics (STML) at 'Buy'; Focus Now on June ASCO Presentation
May 9, 2016 11:43 AM EDTRoth Capital affirms Stemline Therapeutics (Nasdaq: STML) with a Buy rating and $32 price target after the company reported Q1 results on Monday. Stemline posted Q1 EPS of ($0.51), which was $0.08 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $205.65 million, versus $121.43 million reported last year.
Analyst Joseph Pantginis commented, Following a mostly quiet time in 2015 regarding news flow, which we... More
